Table 4.
Associated renoprotective effects of SGLT2 inhibitors, results from randomized controlled trials
| Study | Drugs | Composite outcomea | Progression of albuminuria | dSCr | Renal death | ESKD | 40% eGFR reduction |
|---|---|---|---|---|---|---|---|
| CANVAS Programb [78, 85] | Canagliflozin | 5.5 | 89.4 | 1.2 | 0.4 | 5.3 | |
| Placebo | 9.0 | 128.7 | 2.4 | 0.6 | 8.7 | ||
| P value | 0.3868 | 0.0184 | |||||
| CREDENCE [70] | Canagliflozin | 11.1 | 5.4 | 0.1 | 5.3 | 3.5 | |
| Placebo | 15.5 | 8.5 | 0.2 | 7.5 | 5.7 | ||
| P value | 0.00001 | < 0.001 | 0.002 | ||||
| DECLARE–TIMI 58 [93] | Dapagliflozin | 1.5 | 0.1 | 0.1 | 1.4 | ||
| Placebo | 2.6 | 0.1 | 0.2 | 2.5 | |||
| P value | < 0.0001 | 0.32 | 0.013 | < 0.0001 | |||
| DAPA-CKD [122] | Dapagliflozin | 6.6 | < 0.1 | 5.1 | 5.2 | ||
| Placebo | 11.3 | 0.3 | 7.5 | 9.3 | |||
| P value | < 0.001 | ||||||
| EMPEROR-Reduced [68] | Empagliflozin | 1.6 | |||||
| Placebo | 3.1 | ||||||
| P value | < 0.001 | ||||||
| EMPA-REG OUTCOME [86] | Empagliflozin | 1.7 | 11.2 | 1.5 | |||
| Placebo | 3.1 | 16.2 | 2.6 | ||||
| P value | < 0.001 | < 0.001 | < 0.001 | ||||
| VERTIS CV [11] | Ertugliflozin | 3.2 | 3.1 | 0 | |||
| Placebo | 3.9 | 3.8 | 0 |
dSCr doubling of serum creatinine, ESKD end-stage kidney disease, eGFR estimated glomerular filtration rate
aPrimary renal composite outcome
bRate 1000 people per year
cP value for homogeneity between CANVAS and CANVAS-R